`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`ARGENTUM PHARMACEUTICALS LLC, MYLAN
`PHARMACEUTICALS INC., BRECKENRIDGE PHARMACEUTICAL,
`INC., and ALEMBIC PHARMACEUTICALS, LTD.,
`Petitioners,
`
`v.
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.
`Patent Owner
`
`_______________
`
`Case IPR2016-002041
`Patent RE38,551 E
`_______________
`
`PETITIONER RESPONSE TO
`PATENT OWNER’S IDENTIFICATION OF
`PETITIONERS’ ARGUMENTS AND EVIDENCE REGARDING SCOPE
`AND FORM OF PETITIONER REPLY
`
`
`
`
`
`
`
`1 Case IPR2016-01101, Case IPR2016-01242, and Case IPR2016-01245
`have been joined with this proceeding.
`
`
`
`
`
`I.
`
`PATENT OWNER ARGUMENT JUSTIFYING CITATION TO LEGALL
`
`See Resp. 51-58, 53 (citing Ex.2036 ¶¶305-309); Ex. 2036 ¶¶305
`
`(disagreeing “with Dr. Wang’s conclusion [Ex.1002 ¶132] . . . that R,S BAMP is
`
`the ‘closest prior art’”); Ex.1002 ¶132 (“the closest prior art is racemic lacosamide,
`
`as disclosed in LeGall”); Ex.2036 ¶307-09; Resp. 47, 51-58. Resp. 41 (“Eli Lilly
`
`was well aware of … Petitioner’s so-called ‘racemic lacosamide’ having a
`
`methoxymethyl moiety at the α-carbon, but showed no interest in either compound.
`
`See Ex.2068; Ex.2036 ¶¶272, 293.”). See Resp. 52 (arguing that “a POSA would
`
`have had no reason to expect” lacosamide to exhibit particular properties,
`
`including “high potency”); Ex.1050, at 158, 159, 208-216 (same); Resp. 54
`
`(“skepticism”).
`
`II.
`
`PATENT OWNER ARGUMENT JUSTIFYING CITATION TO ’301 PATENT
`
`Resp. 28-29 (arguing a POSA “would not have changed the methoxyamino
`
`to a methoxymethyl as Petitioner proposes”); id. at 36 (“a POSA would not have
`
`reasonably expected success in substituting methoxyamino with methoxymethyl”);
`
`Pet. 46-47 (“methoxymethyl is specifically claimed at the α-carbon position in the
`
`’301 patent”); id. at 19-21; Resp. 52-54 (unexpected results, citing Exs. 2036 and
`
`2038); Resp. 58-60 (commercial success and identifying ‘301 patent as blocking
`
`patent); Resp. 59 (characterizing size of genus of ‘301 patent).
`
`
`
`1
`
`
`
`
`
`III. PATENT OWNER ARGUMENT JUSTIFYING RELIANCE ON KEPPRA
`E.g., Resp. 57 (asserting that certain properties “were not exhibited by any
`
`other single prior art AED”) (citing Ex.2038 ¶¶70–76, 96-99); Resp. 6-8, 51-58
`
`(secondary considerations) (citing Exs.2036 and 2038); Ex.1048, at 235-239.
`
`IV. PETITIONER COMPLIED WITH RULES REGARDING WORD COUNT
`Patent Owner complains about the citation form “Ex.##” but cites no PTAB
`
`rule. Petitioner’s citation format conforms with the analogous Federal Circuit rule.
`
`See Fed. Cir. R. 28 (f) (requiring appendix citations to be “as short as possible
`
`consistent with clarity and must follow the numbering format specified in Federal
`
`Circuit Rule 30(b)(4)(E), e.g., ‘Appx134,’ ‘Appx3-17’ or ‘SAppx1185’”).
`
`Patent Owner itself changed its citation format (from “¶ #” to “¶#”) to
`
`eliminate spaces in its Patent Owner Response. Compare Patent Owner
`
`Preliminary Response at 3, 12, 20, 25, 43, 46, 49, 55, with Patent Owner Response
`
`at passim (over 100 instances of no space between “¶” and number).
`
`Patent Owner cites to images, but Petitioner “may rely on the word count of
`
`the word-processing system used to prepare the paper.” 37 C.F.R. § 42.24(d).
`
`Petitioner was 70 words under the limit. See Reply, Certificate of Word Count
`
`(“5,530 words”). Patent Owner’s own image would, if deconstructed, cause the
`
`Response to exceed its word limit. See Resp. 11. Further, the images do not add
`
`text to the brief but merely act as citations to portions of exhibits in the record.
`
`
`
`2
`
`
`
`
`
`Dated: December 9, 2016
`
`By:
`
`
`
`
`
`
`
`
`
`
`
`
`/Matthew J. Dowd/
`Matthew J. Dowd
`Reg. No. 47,534
`Dowd PLLC
`1717 Pennsylvania Avenue, NW
`Suite 1025
`Washington, DC 20006
`Phone: (202) 573-3853
`mjdowd@dowdpllc.com
`
`William G. Jenks
`Reg. No. 48,818
`Jenks IP Law
`1050 17th ST NW
`Suite 800
`Washington, D.C. 20036
`Phone: (202) 412-7964
`wjenks@jenksiplaw.com
`
`Counsel for Petitioner
`
`3
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on this 9th day of December 2016, the foregoing
`
`PETITIONER RESPONSE TO
`PATENT OWNER’S IDENTIFICATION OF
`PETITIONERS’ ARGUMENTS AND EVIDENCE REGARDING SCOPE
`AND FORM OF PETITIONER REPLY
`
`
`
`was served by electronic mail on the following counsel of record for Patent Owner:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Andrea G. Reister (areister@cov.com)
`Jennifer L. Robbins (jrobbins@cov.com)
`Enrique D. Longton (elongton@cov.com)
`Covington & Burling LLP
`One CityCenter
`850 Tenth Street NW
`Washington, DC 20001
`(202) 662-6000
`
`Dated: December 9, 2016
`
`
`
`By:
`
`
`/Matthew J. Dowd/
`Matthew J. Dowd
`Reg. No. 47,534
`Dowd PLLC
`1717 Pennsylvania Ave, NW
`Suite 1025
`Washington, DC 20006
`Phone: (202) 573-3853
`mjdowd@dowdpllc.com
`
`4